Welcome to our dedicated page for Rockwell Med SEC filings (Ticker: RMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rockwell Medical, Inc. (Nasdaq: RMTI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Rockwell Medical files current reports on Form 8-K and periodic reports such as Form 10-Q, which together offer detailed information on its financial condition, operating performance, corporate governance, and key business developments related to its hemodialysis products for dialysis providers worldwide.
Through Rockwell Medical’s Form 8-K filings, users can review disclosures about material events, including quarterly financial results, updated corporate presentations, and changes in the composition of the board of directors or executive leadership. For example, the company has used Form 8-K to announce financial results for specific quarters, to furnish investor presentations, and to report appointments and resignations of directors and senior officers, along with related compensation and equity awards.
Quarterly reports on Form 10-Q, referenced in Rockwell Medical’s announcements, contain more extensive financial statements and notes, as well as management’s discussion of net sales, gross profit, gross margin, operating income or loss, adjusted EBITDA, and cash position. These filings also provide context on customer contracts, such as the impact of large customers transitioning to other suppliers and the extent of long-term agreements with dialysis providers.
On Stock Titan, Rockwell Medical’s SEC filings are presented with real-time updates from the EDGAR system and AI-powered summaries that explain the key points in plain language. Users can quickly understand the implications of a new 8-K or 10-Q, see how financial metrics are trending, and identify disclosures about corporate governance or compensation arrangements. This page is a resource for investors and analysts who want to examine Rockwell Medical’s official regulatory history and interpret the company’s hemodialysis-focused business through its SEC reports.
Rockwell Medical, Inc. furnished an updated corporate presentation as part of a current report. The presentation, dated March 26, 2026, is attached as Exhibit 99.1 and provides corporate information under Regulation FD.
The company notes this material is furnished, not filed, so it is not subject to certain Exchange Act liabilities and will only be incorporated into other securities filings if specifically referenced.
Rockwell Medical details its hemodialysis concentrates business, 2025 milestones, and mounting risks in its annual report. The company serves 294 customers, including all five leading U.S. dialysis providers, with dialysate concentrates making up 100% of 2025 revenue and about 88% of sales in the United States.
DaVita accounted for 16% of 2025 net product sales, down from 45% in 2024, after an attempted transition to another supplier. A second amendment extended Rockwell’s DaVita supply agreement through December 31, 2026 with higher pricing. Rockwell ended manufacturing at its South Carolina facility to streamline costs and added 30 new western U.S. customers.
At December 31, 2025, Rockwell reported about $25.0 million in cash, cash equivalents and available-for-sale investments, working capital of $28.6 million, and net cash used in operations of roughly $0.7 million for the year. Management believes capital is sufficient for at least 12 months but warns that additional funding, covenant compliance under its Innovatus term loan, customer concentration, cost inflation, and evolving kidney disease treatments could materially affect future results.
Rockwell Medical, Inc. reported fourth quarter and full-year 2025 results showing a sharp revenue decline but improved margins and positive cash generation. Net sales were $18.3 million in Q4 2025 versus $24.7 million a year earlier, and $69.3 million for 2025 compared with $101.5 million in 2024, mainly due to lower purchase volume from one customer.
Q4 2025 gross margin improved to 21% from 15%, with full-year 2025 gross margin steady at 17%. The company posted a 2025 net loss of $5.3 million versus $0.5 million in 2024, but remained profitable on an Adjusted EBITDA basis at $0.3 million. Cash, cash equivalents and investments were $25.0 million at December 31, 2025, up from $21.6 million. For 2026, Rockwell guides to Adjusted EBITDA of $1 million to $2 million and positive operating cash flow.
ROCKWELL MEDICAL, INC. Chief Operating Officer Heather Hunter reported a routine tax-related share disposition. On the vesting of restricted stock units, 2,444 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations. After this withholding, she held 130,079 common shares directly.
ROCKWELL MEDICAL, INC. officer Megan C. Timmins reported a routine tax-related share disposition. On this Form 4, 3,667 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations tied to the vesting of restricted stock units, rather than being sold on the market. After this withholding, Timmins directly holds 162,408 shares of Rockwell Medical common stock.
Rockwell Medical Senior Vice President and CFO Jesse Neri reported a routine tax-related share withholding. On the vesting of restricted stock units, 2,444 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations. After this non-market disposition, Neri directly holds 122,398 shares of Rockwell Medical common stock.
ROCKWELL MEDICAL, INC. senior vice president and chief commercial officer Timothy Chole reported a routine tax-related share disposition. On the vesting of restricted stock units, 2,444 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations. Following this withholding, he directly holds 122,855 shares of Rockwell Medical common stock.
ROCKWELL MEDICAL, INC. reported a routine tax-related share disposition by its President and CEO, Mark Strobeck. On the reported date, 7,333 shares of common stock were withheld in connection with the vesting of restricted stock units to cover estimated tax obligations, rather than being sold on the open market. Following this withholding, Strobeck directly owns 323,493 shares of Rockwell Medical common stock.
Rockwell Medical, Inc. submitted a current report describing that it has issued a press release with preliminary, unaudited financial results for the quarter and full year ended December 31, 2025. These figures are based on management’s initial analysis and remain subject to the company’s normal quarter-end and year-end closing procedures, internal review, and audit by its independent registered public accounting firm, so actual results may differ from the preliminary figures in the press release.
The report clarifies that the information under the results section and the attached press release are being furnished, not filed, which affects how they are treated under securities laws. It also highlights that the press release includes forward-looking statements about future financial condition, operating results, revenue growth, profitability, cost reductions, and product diversification, all of which are subject to risks described in Rockwell Medical’s prior SEC filings.
Rockwell Medical director reports new equity awards
A director of Rockwell Medical, Inc. (RMTI) reported receiving equity compensation on November 17, 2025. The filing shows an award of 25,000 shares of common stock, described as restricted stock units that vest on November 17, 2026, subject to continued service. After this grant, the director beneficially owns 25,000 common shares directly.
The director was also granted stock options for 25,000 shares of common stock at an exercise price of $0.87 per share, expiring on November 17, 2035. These options vest on November 17, 2026, also conditioned on continued service. The Form 4 notes that it is being filed late due to administrative delays in obtaining the director’s EDGAR codes.